BLU 667

Drug Profile

BLU 667

Latest Information Update: 25 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Blueprint Medicines
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Solid tumours; Thyroid cancer

Most Recent Events

  • 20 Mar 2017 Phase-I clinical trials in Thyroid cancer, Solid Tumours and Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT03037385)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top